Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.

Therapeutic drug monitoring - 1 Feb 2016

Mannheimer Buster, Haslemo Tore, Lindh Jonatan D, Eliasson Erik, Molden Espen

Abstract excerpt

PURPOSE: To investigate the predictive value of the risperidone and venlafaxine metabolic ratios and CYP2D6 genotype. METHODS: The determination of risperidone, 9-hydroxyrisperidone, and venlafaxine, O-desmethylvenlafaxine, N-desmethylvenlafaxine and CYP2D6 genotype was performed in 425 and 491 patients, respectively. The receiver operator characteristic method and the area under the receiver operator...

Topics

Join the communities discussing this publication.

Antidepressive Agents, Second-Generation
Antipsychotic Agents
Cyclohexanols
Cytochrome P-450 CYP2D6
Predictive Value of Tests

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Sensitivity and Specificity

Venlafaxine Hydrochloride

Source

Identifiers

PMID: 26418700
DOI: 10.1097/FTD.0000000000000251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.PMID 26418700Read ↗

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.Semantic proximity Read ↗

Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype.Semantic proximity Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates.Semantic proximity Read ↗

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.Semantic proximity Read ↗

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.Semantic proximity Read ↗

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.Semantic proximity Read ↗

Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.Semantic proximity Read ↗

The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.Semantic proximity Read ↗

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity Read ↗

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Semantic proximity Read ↗

Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.